Date:8/17/2010

to suppliers (361,417) -- Inventories 732,041 1,084,961 Other receivables (3,326,248) (513,093) Accounts payable 1,492,701 437,914 Notes payable (1,613,150) 10,229,087 Advance from customers 727,868 188,658 Income tax payable 227,259 358,439 Other payables 269,815 (9,203) Net cash (used in)/provided by operating activities (532,070) 2,589,802 Cash flows from investing activities: Purchase of property and equipment (1,369,347) (1,146,764) Net cash used in investing activities (1,369,347) (1,146,764) Cash flows from financing activities: Proceeds from bank loans 22,428,651 730,648 Repayment of bank loans (17,002,601) -- Repayment in amount due to a related party (1,630,614) (5,597,857) Loan from employees 20,517 (38,566) Net cash provided by financing activities 3,815,953 (4,905,775) Effect of exchange rate fluctuation on cash and cash equivalent 80,053 8,420 Net increase/(decrease) in cash and cash equivalent 1,994,589 (3,454,317) Cash and cash equivalent- beginning of period 10,174,528 5,319,456 Cash and cash equivalent-end of period 12,169,117 1,865,139 Supplemental disclosure of cash flow information: Cash paid for interest expense $1,129,181 $1,249,083 Cash paid for income tax $896,164 $515,713 Supplemental disclosure of non-cash investing and financing activities $888,960 $-- Repayment in amount due to related party by transferring out long-term investment at cost Collection in amount due from related party by receiving the ownership in real estate property at fair value $-- $36,710,934 For more information, please contact: COMPANY: Ms. Crystal Tang, VP of Finance China Ruitai International Holdings Co, Ltd 1221 Avenue of Americas Suite 4200 New York, NY 10020 Web: http://www.rutocel.com Phone: +1-212-899-5131 Email: tmqcrui@gmail.com crystal@rutocel.com INVESTOR RELATIONS: Mr. John Mattio, Senior Vice President HC International, Inc. New York and
'/>"/>

SOURCE China Ruitai International Holdings Co., Ltd. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth